Study reveals how changes in gene can lead to blindness in middle age

Blindness study shows how gene causes middle-age sight loss.

Chemical changes in the eye that can lead to blindness have been identified by scientists, a conference has heard.

Their findings aid understanding of a genetic condition that causes sight loss for one in 3,000 people in the UK. It was presented at the Eye Development and Degeneration 2017 conference in Edinburgh on Tuesday.

Scientists examined how changes in a gene known as RPGR damage eye cells to cause a disorder known as X-linked retinitis pigmentosa. The condition is incurable and affects night and peripheral vision before gradually causing blindness in middle age.

Researchers led by the University of Edinburgh took skin samples from two patients and transformed stem cells - which can change into any cell type - into light-sensing eye cells known as photoreceptors. They compared these with cells from healthy relatives of the patients.

Photoreceptors - which decay in retinitis pigmentosa patients - differed in their fundamental structure when compared with those from family members.

Follow-up studies in mice identified key molecules that interact with RPGR to maintain the structure of photoreceptors. When RPGR is flawed, the structure is compromised and photoreceptors cannot function correctly, leading to sight loss.

Dr Roly Megaw from the University of Edinburgh's Medical Research Council Institute for Genetics and Molecular Medicine, who led the study, said: "By furthering our understanding of the RPGR gene and its effects on photoreceptor cells, we hope our findings bring us closer to developing a possible treatment for this devastating disease."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study links pulmonary carcinoid aggressiveness to TERT gene activation